Reviews in Endocrine and Metabolic Disorders https://doi.org/10.1007/s11154-020-09620-2 CORRECTION Correction to: Endocrine and metabolic aspects of the COVID-19 pandemic Mónica Marazuela 1 & Andrea Giustina 2 & Manuel Puig-Domingo 3 # Springer Science+Business Media, LLC, part of Springer Nature 2021 Correction to: Rev Endocr Metab Disord (2020) 21:495–507 https://doi.org/10.1007/s11154-020-09569-2 While preparing the manuscript an error in the reorganization receiving antithyroid drugs, because symptoms of the rare side of a section altered its correct presentation. In that way the first effect of agranulocytosis can overlap with COVID-19. In this 11 lines of section 7 of the paper should read: scenario, if symptoms of COVID-19, agranulocytosis should As previously reported by Pal and Banerjee (65) few data on be ruled out immediately with a full blood count. possible effects of coronaviruses on the thyroid are available. Thyroid hormones were reported to be decreased in patients ORIGINAL TEXT affected by SARS during acute infection and recovery sug- Data on thyroid involvement by coronavirus are most scarce. gesting an euthyroid sick syndrome. A study conducted during the SARS outbreak in 2003 had However, damaged but not reduced in size thyroid cells were reported that serum Triiodothyronine and thyroxine levels found at an autoptic study on five SARS patients [71,72]. were lower in patients with SARS as compared to controls, Functional and pathological thyroid data in COVID-19 are both during the acute and convalescent phases. This could in the process to be collected [65]. simply imply an underlying euthyroid sick syndrome. Regarding Graves’ disease, COVID-19 can be a precipitating However, a study of the autopsy in five patients with SARS factor for initiation or relapse of the disease (M. Marazuela, has shown marked destruction of the follicularand personal experience). Several medical societies have recom- parafollicular thyroid cells [71] and not a reduction in thyroid mended to take special care to patients with hyperthyroidism follicular size associated with euthyroid sick syndrome [72]. Destruction of follicular cells may also be identified as a low The online version of the original article can be found at https://doi.org/ triiodothyronine and thyroxine profile. Data on thyroid func- 10.1007/s11154-020-09569-2 tion or thyroid pathology are yet not available in COVID-19 [65]. * Mónica Marazuela Regarding Graves’ disease, COVID-19 can be a precipitating monica.marazuela@salud.madrid.org factor for initiation or relapse of the disease (M. Marazuela, personal experience). Several medical societies have recom- 1 Department of Endocrinology, Hospital Universitario de la Princesa, mended to take special care to patients with hyperthyroidism Instituto de Investigación de la Princesa, Universidad Autónoma de receiving antithyroid drugs, because symptoms of the rare side Madrid, Madrid, Spain effect of agranulocytosis can overlap with COVID-19. In this 2 Division of Endocrinology IRCCS San Raffaele Hospital, Institute of scenario, if symptoms of COVID-19, agranulocytosis should Endocrine and Metabolic Sciences Vita Salute San Raffaele be ruled out immediately with a full blood count. University, Milan, Italy 3 Endocrinology and Nutrition Service, Department of Medicine, Germans Trias i Pujol Research Institute and Hospital, Universitat Publisher’s note Springer Nature remains neutral with regard to jurisdic- Autònoma de Barcelona, Badalona, Spain tional claims in published maps and institutional affiliations.